Byondis World ADC Highlights

Byondis BV, an independent, clinical stage biopharmaceutical company creating targeted medicines, announced that results of its pivotal Phase III TULIP® study involving ADC [vic-]trastuzumab duocarmazine (SYD985) will be presented at the 12th World ADC San Diego Digital Edition conference, October 11-14. The trial, which compared SYD985 to physician's choice (PC) treatment, demonstrated a statistically significant improvement in progression-free survival (PFS) over PC. The company will also present on the preclinical profile of ADC SYD1875 and on its proprietary, site-specific ADC conjugation platform, ByonShieLD®, which is employed in SYD1875.

Details follow:

Monday, 11 October, 12:30 PM EDT / 6:30 PM CET

“Preclinical Profile of SYD1875, a Novel Site-Specifically Conjugated Anti-5T4 Antibody Drug Conjugate,” Patrick Groothuis, Ph.D., Byondis Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetics

Tuesday, 12 October, 12:00 PM EDT / 6:00 PM CET

“ByonShieLD®, A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines,” Ruud Coumans, Ph.D., Byondis Project Leader, Antibody-Drug Conjugates

Wednesday, 13 October, 8:30 AM EDT / 2:30 PM CET

“Primary Outcome of the Phase III SYD985.002/TULIP® Study Comparing [vic-]trastuzumab duocarmazine to Physician’s Choice Treatment in Patients with Pre-treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,” Evelyn van den Tweel, Ph.D., Byondis Project Leader, Clinical Development